(UroToday.com) Sabizabulin (VERU-111) is an oral cytoskeletal disruptor that disrupts microtubules supporting the cytoskeleton and has no affinity for multidrug resistance proteins. Additionally, it has been shown to cleave poly (ADTP-ribose) polymerase (PARP) protein, with a favorable toxicity profile with no neurotoxicity and no neutropenia or myelosuppression. The following schematic depicts sabizabulin targeting microtubules and disrupting transport of androgen receptors into the nucleus: